Supplemental Table 1 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
openalex（2023）
摘要
Supplemental Table 1. Additional study results on treatment-related adverse events at dose levels below the maximum tolerated dose
更多查看译文
关键词
dual inhibitor,cancer,mtor,first-in-human,small-molecule
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要